Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2016

  • ID: 3960450
  • Report
  • 722 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AB Science SA
  • BioNTech AG
  • F. Hoffmann-La Roche Ltd.
  • Incyte Corporation
  • MedImmune LLC
  • Oncolytics Biotech Inc.
  • MORE
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2016, provides an overview of the Head And Neck Cancer Squamous Cell Carcinoma (Oncology) pipeline landscape.

Head and Neck Cancer Squamous Cell Carcinoma is a cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx. The common symptoms of cancer of the head and neck include persistent pain in the throat, pain or difficulty with swallowing, persistent hoarseness or a change in voice, pain in the ear and bleeding in the mouth or throat. The disease may be controlled by chemotherapy and radiation therapy.

Report Highlights:

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Head And Neck Cancer Squamous Cell Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Head And Neck Cancer Squamous Cell Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 14, 49, 49, 2, 23, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 2, 4 and 2 molecules, respectively.Head And Neck Cancer Squamous Cell Carcinoma.

Head And Neck Cancer Squamous Cell Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Head And Neck Cancer Squamous Cell Carcinoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Head And Neck Cancer Squamous Cell Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Head And Neck Cancer Squamous Cell Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Head And Neck Cancer Squamous Cell Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Head And Neck Cancer Squamous Cell Carcinoma (Oncology)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Head And Neck Cancer Squamous Cell Carcinoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Head And Neck Cancer Squamous Cell Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AB Science SA
  • BioNTech AG
  • F. Hoffmann-La Roche Ltd.
  • Incyte Corporation
  • MedImmune LLC
  • Oncolytics Biotech Inc.
  • MORE
Introduction

Head And Neck Cancer Squamous Cell Carcinoma Overview

Therapeutics Development

Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Development by Companies

Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Products Glance

Head And Neck Cancer Squamous Cell Carcinoma - Products under Development by Companies

Head And Neck Cancer Squamous Cell Carcinoma - Products under Investigation by Universities/Institutes

Head And Neck Cancer Squamous Cell Carcinoma - Companies Involved in Therapeutics Development

Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics Assessment

Drug Profiles

Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects

Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products

Head And Neck Cancer Squamous Cell Carcinoma - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma, H2 2016

Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Development by Companies, H2 2016 (Contd..1)

Number of Products under Development by Companies, H2 2016 (Contd..2)

Number of Products under Development by Companies, H2 2016 (Contd..3)

Number of Products under Development by Companies, H2 2016 (Contd..4)

Number of Products under Development by Companies, H2 2016 (Contd..5)

Number of Products under Development by Companies, H2 2016 (Contd..6)

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Comparative Analysis by Unknown Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016 (Contd..1)

Products under Development by Companies, H2 2016 (Contd..2)

Products under Development by Companies, H2 2016 (Contd..3)

Products under Development by Companies, H2 2016 (Contd..4)

Products under Development by Companies, H2 2016 (Contd..5)

Products under Development by Companies, H2 2016 (Contd..6)

Products under Development by Companies, H2 2016 (Contd..7)

Products under Development by Companies, H2 2016 (Contd..8)

Products under Development by Companies, H2 2016 (Contd..9)

Products under Investigation by Universities/Institutes, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AB Science SA, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AbbVie Inc, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Accelerated Pharma, Inc., H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Acceleron Pharma, Inc., H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Adaptimmune Therapeutics Plc, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Advaxis, Inc., H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Altor BioScience Corporation, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Amgen Inc., H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AstraZeneca Plc, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AVEO Pharmaceuticals, Inc., H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Bayer AG, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Bionovis SA, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by BioNTech AG, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Boehringer Ingelheim GmbH, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Bristol-Myers Squibb Company, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Calithera Biosciences, Inc., H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by CEL-SCI Corporation, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Cellceutix Corporation, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Celldex Therapeutics, Inc., H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Centrose LLC, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Critical Outcome Technologies Inc., H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by CytImmune Sciences, Inc., H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Daiichi Sankyo Company, Limited, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Eisai Co., Ltd., H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Eleven Biotherapeutics Inc., H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Eli Lilly and Company, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Etubics Corporation, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by G&E Herbal Biotechnology Co., Ltd., H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by GeneSegues Inc, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Genexine, Inc., H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Genmab A/S, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by GlaxoSmithKline Plc, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Gliknik, Inc., H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Glycotope GmbH, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Horizon Pharma Plc, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Immunomedics, Inc., H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Immunovative Therapies, Ltd., H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Incyte Corporation, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Infinity Pharmaceuticals, Inc., H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Innate Pharma S.A., H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Inovio Pharmaceuticals, Inc., H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by IRX Therapeutics, Inc., H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Johnson & Johnson, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Kolltan Pharmaceuticals, Inc., H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Laboratoires Pierre Fabre SA, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Loxo Oncology, Inc., H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Mabion SA, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by MacroGenics, Inc., H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Marsala Biotech Inc., H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Mateon Therapeutics Inc, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by MedImmune LLC, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Merck & Co., Inc., H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Merck KGaA, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Mirati Therapeutics Inc., H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Molecular Partners AG, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Molplex Ltd., H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by NanoCarrier Co., Ltd., H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Novartis AG, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Oncobiologics, Inc., H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Oncolytics Biotech Inc., H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Onconova Therapeutics, Inc., H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by OncoSec Medical Incorporated, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Panacea Biotec Limited, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by PCI Biotech Holding ASA, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Pfizer Inc., H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Reliance Life Sciences Pvt. Ltd., H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Sanofi, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Shanghai Henlius Biotech Co., Ltd., H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Shionogi & Co., Ltd., H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Sillajen Biotherapeutics, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Symphogen A/S, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by SynCore Biotechnology Co., Ltd., H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Takara Bio Inc., H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Transgene SA, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by UbiVac, LLC, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by VasGene Therapeutics, Inc., H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by VentiRx Pharmaceuticals, Inc., H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Virttu Biologics Limited, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Vyriad Inc, H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects (Contd..1), H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects (Contd..2), H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects (Contd..3), H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects (Contd..4), H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products (Contd..1), H2 2016

List of Figures

Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma, H2 2016

Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Top 10 Routes of Administration, H2 2016

Number of Products by Stage and Top 10 Routes of Administration, H2 2016

Number of Products by Top 10 Molecule Types, H2 2016

Number of Products by Stage and Top 10 Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
- AB Science SA
- AbbVie Inc
- Accelerated Pharma, Inc.
- Acceleron Pharma, Inc.
- Adaptimmune Therapeutics Plc
- Advaxis, Inc.
- Altor BioScience Corporation
- Amgen Inc.
- AstraZeneca Plc
- AVEO Pharmaceuticals, Inc.
- Bayer AG
- Bionovis SA
- BioNTech AG
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Calithera Biosciences, Inc.
- CEL-SCI Corporation
- Cellceutix Corporation
- Celldex Therapeutics, Inc.
- Centrose LLC
- Critical Outcome Technologies Inc.
- CytImmune Sciences, Inc.
- Daiichi Sankyo Company, Limited
- Eisai Co., Ltd.
- Eleven Biotherapeutics Inc.
- Eli Lilly and Company
- Etubics Corporation
- F. Hoffmann-La Roche Ltd.
- G&E Herbal Biotechnology Co., Ltd.
- GeneSegues Inc
- Genexine, Inc.
- Genmab A/S
- GlaxoSmithKline Plc
- Gliknik, Inc.
- Glycotope GmbH
- Hanmi Pharmaceuticals, Co. Ltd.
- Horizon Pharma Plc
- Immunomedics, Inc.
- Immunovative Therapies, Ltd.
- Incyte Corporation
- Infinity Pharmaceuticals, Inc.
- Innate Pharma S.A.
- Inovio Pharmaceuticals, Inc.
- IRX Therapeutics, Inc.
- Johnson & Johnson
- Kolltan Pharmaceuticals, Inc.
- Laboratoires Pierre Fabre SA
- Loxo Oncology, Inc.
- Mabion SA
- MacroGenics, Inc.
- Marsala Biotech Inc.
- Mateon Therapeutics Inc
- MedImmune LLC
- Merck & Co., Inc.
- Merck KGaA
- Merrimack Pharmaceuticals, Inc.
- Millennium Pharmaceuticals Inc
- Mirati Therapeutics Inc.
- Molecular Partners AG
- Molplex Ltd.
- NanoCarrier Co., Ltd.
- Novartis AG
- Oncobiologics, Inc.
- Oncolytics Biotech Inc.
- Onconova Therapeutics, Inc.
- OncoSec Medical Incorporated
- Ono Pharmaceutical Co., Ltd.
- Panacea Biotec Limited
- PCI Biotech Holding ASA
- Pfizer Inc.
- Reliance Life Sciences Pvt. Ltd.
- Sanofi
- Shanghai Henlius Biotech Co., Ltd.
- Shionogi & Co., Ltd.
- Sillajen Biotherapeutics
- Symphogen A/S
- SynCore Biotechnology Co., Ltd.
- Takara Bio Inc.
- Tara Immuno-Oncology Therapeutics LLC
- Transgene SA
- UbiVac, LLC
- VasGene Therapeutics, Inc.
- VentiRx Pharmaceuticals, Inc.
- Virttu Biologics Limited
- Vyriad Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll